Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($6.81) EPS for the quarter, missing the consensus estimate of ($6.25) by ($0.56), Zacks reports.
Theriva Biologics Stock Down 2.1 %
Theriva Biologics stock opened at $1.40 on Thursday. Theriva Biologics has a twelve month low of $1.24 and a twelve month high of $17.11. The firm has a market capitalization of $3.18 million, a price-to-earnings ratio of -0.04 and a beta of 1.34.
Analysts Set New Price Targets
Separately, Maxim Group reduced their price target on shares of Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday.
Theriva Biologics Company Profile
Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.
Further Reading
- Five stocks we like better than Theriva Biologics
- What Is WallStreetBets and What Stocks Are They Targeting?
- Insiders Bet Big on These Small Cap Stocks
- Which Wall Street Analysts are the Most Accurate?
- Can United States Cellular Ride Higher on Its Spectrum Strategy?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- HubSpot’s Growth in CRM: Can It Compete With Salesforce?
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
